Skip to main content
HR 1035 116th Congress House Health Administrative remedies Consumer affairs Contracts and agency Health care costs and insurance Health information and medical records Insurance industry and regulation Medical ethics Medicare Prescription drugs Public contracts and procurement Retail and wholesale trades

Prescription Drug Price Transparency Act

Introduced: April 3, 2019 See on congress.gov
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 7, 2019
Referred to the Subcommittee on Health.
Feb 7, 2019
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Oversight and Reform, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Feb 7, 2019
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Prescription Drug Price Transparency Act

This bill establishes additional requirements for prescription drug plan sponsors (PDPs) under Medicare and Medicare Advantage, as well as health insurance carriers under the Federal Employees Health Benefits Program, relating to the methodology of payments to pharmacies and the use of pharmacy benefits managers (PBMs).

Specifically, such PDPs and carriers must disclose specified information to pharmacies regarding applicable standards for reimbursement that are based on drug costs, including the sources used to update such standards. Additionally, such PDPs and carriers may not contract with PBMs that require, or that provide an incentive for, plan enrollees to use pharmacies that have a shared ownership interest with the PBM.

What's happening now February 7, 2019

Referred to the Subcommittee on Health.

 Related & companion bills 3
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 4
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 1035: Prescription Drug Price Transparency Act. 116th Congress. Open America. https://openamerica.io/bill/116-HR-1035/
MLA
"H.R. 1035: Prescription Drug Price Transparency Act." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-1035/.
Bluebook (legal)
H.R. 1035, 116th Cong. (2026), https://openamerica.io/bill/116-HR-1035/.
Markdown link
[H.R. 1035: Prescription Drug Price Transparency Act](https://openamerica.io/bill/116-HR-1035/)
Report a problem